Kevin Tan - 09 Jan 2024 Form 4 Insider Report for Solid Biosciences Inc. (SLDB)

Role
CFO & Treasurer
Signature
/s/ David Tyronne Howton as attorney-in-fact for Kevin Tan
Issuer symbol
SLDB
Transactions as of
09 Jan 2024
Net transactions value
-$32,267
Form type
4
Filing time
11 Jan 2024, 17:43:08 UTC
Previous filing
11 Jan 2023
Next filing
16 Feb 2024
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction SLDB Common Stock Options Exercise +11,250 +564% 13,243 09 Jan 2024 Direct F1, F2
transaction SLDB Common Stock Sale $32,267 -3,935 -30% $8.20 9,308 09 Jan 2024 Direct F2, F3

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction SLDB Restricted Stock Units Options Exercise $0 -11,250 -25% $0.000000 33,750 09 Jan 2024 Common Stock 11,250 Direct F1, F4
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Restricted stock units convert to common stock on a one-for-one basis.
F2 Includes 1,993 shares of common stock acquired under the Solid Biosciences Inc. Employee Stock Purchase Plan on November 30, 2023.
F3 This sale was made to cover withholding taxes following the vesting of the previously granted restricted stock units. The sales do not represent a discretionary trade by Mr. Tan.
F4 The restricted stock units were granted on January 9, 2023 (the "Grant Date") and vest over four years, with 25% of the original number of shares vesting on each anniversary of the Grant Date until the fourth such anniversary.